GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Candel Therapeutics Inc (NAS:CADL) » Definitions » PB Ratio

CADL (Candel Therapeutics) PB Ratio : 3.71 (As of Apr. 03, 2025)


View and export this data going back to 2021. Start your Free Trial

What is Candel Therapeutics PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2025-04-03), Candel Therapeutics's share price is $5.25. Candel Therapeutics's Book Value per Share for the quarter that ended in Dec. 2024 was $1.42. Hence, Candel Therapeutics's PB Ratio of today is 3.71.

Good Sign:

Candel Therapeutics Inc stock PB Ratio (=3.66) is close to 1-year low of 3.66.

The historical rank and industry rank for Candel Therapeutics's PB Ratio or its related term are showing as below:

CADL' s PB Ratio Range Over the Past 10 Years
Min: 0.84   Med: 1.8   Max: 14.61
Current: 3.7

During the past 6 years, Candel Therapeutics's highest PB Ratio was 14.61. The lowest was 0.84. And the median was 1.80.

CADL's PB Ratio is ranked worse than
68.04% of 1283 companies
in the Biotechnology industry
Industry Median: 2.22 vs CADL: 3.70

During the past 12 months, Candel Therapeutics's average Book Value Per Share Growth Rate was 223.50% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -14.10% per year.

During the past 6 years, the highest 3-Year average Book Value Per Share Growth Rate of Candel Therapeutics was -14.10% per year. The lowest was -14.10% per year. And the median was -14.10% per year.

Back to Basics: PB Ratio


Candel Therapeutics PB Ratio Historical Data

The historical data trend for Candel Therapeutics's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Candel Therapeutics PB Ratio Chart

Candel Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
PB Ratio
Get a 7-Day Free Trial - 3.50 1.08 3.36 6.13

Candel Therapeutics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.36 7.75 - - 6.13

Competitive Comparison of Candel Therapeutics's PB Ratio

For the Biotechnology subindustry, Candel Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Candel Therapeutics's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Candel Therapeutics's PB Ratio distribution charts can be found below:

* The bar in red indicates where Candel Therapeutics's PB Ratio falls into.


;
;

Candel Therapeutics PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Candel Therapeutics's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Dec. 2024)
=5.25/1.417
=3.71

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Candel Therapeutics  (NAS:CADL) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Candel Therapeutics PB Ratio Related Terms

Thank you for viewing the detailed overview of Candel Therapeutics's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Candel Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
117 Kendrick Street, Suite 450, Needham, MA, USA, 02494
Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.
Executives
Paul Peter Tak director, officer: President & CEO CANDEL THERAPEUTICS, INC., 117 KENDRICK ST SUITE 450, NEEDHAM MA 02494
William Garrett Nichols officer: Chief Medical Officer C/O CANDEL THERAPEUTICS, INC., 117 KENDRICK ST SUITE 450, NEEDHAM MA 02494
Francesca Barone officer: Chief Scientific Officer CANDEL THERAPEUTICS, INC., 117 KENDRICK ST SUITE 450, NEEDHAM MA 02494
Seshu Tyagarajan officer: See Remarks CANDEL THERAPEUTICS, INC., 117 KENDRICK ST SUITE 450, NEEDHAM MA 02494
Paul B Manning director 200 GARRETT STREET SUITE S, CHARLOTTESVILLE VA 22902
Estuardo Aguilar-cordova director, officer: Chief Scientific Officer CANDEL THERAPEUTICS, INC., 117 KENDRICK ST SUITE 450, NEEDHAM MA 02494
Nicoletta Loggia director CANDEL THERAPEUTICS, INC., 117 KENDRICK ST., SUITE 450, NEEDHAM MA 02494
Jason Amello officer: Chief Financial Officer 500 KENDALL STREET, CAMBRIDGE MA 01824
Christopher Martell director CANDEL THERAPEUTICS, INC., 117 KENDRICK ST SUITE 450, NEEDHAM MA 02494
Joseph C Papa director C/O BLCO, 400 SOMERSET CORPORATE BLVD., BRIDGEWATER NJ 08807
Gary J. Nabel director C/O SIGA TECHNOLOGIES, INC., 31 EAST 62ND STREET, NEW YORK NY 10065
Renee Gaeta director C/O MOTIVA USA LLC, 16192 COASTAL HIGHWAY, LEWES DE 19958
Nathan Caffo officer: Chief Business Officer C/O ALX ONCOLOGY HOLDINGS INC., 866 MALCOLM ROAD, SUITE 100, BURLINGAME CA 94010
Diem Nguyen director C/O VERRICA PHARMACEUTICALS INC., 10 NORTH HIGH STREET, SUITE 200, WEST CHESTER PA 19380
John J Canepa officer: Chief Financial Officer 241 MATTINSON DRIVE, CONCORD MA 01742